[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rickets\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rickets":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100344931","early-phase-1-the-impact-of-phosphate-metabolism-on-healthy-aging-100344931",false,"NCT03771105","The Impact of Phosphate Metabolism on Healthy Aging","Inclusion Criteria:\n\n* Children above the age of 13 years\n* Younger and older adults with XLH and HHRH with confirmed NPT2c mutations affecting both copies of the NPT2c gene (HHRH) or one copy of the PHEX gene (XLH)\n* Be willing to provide access to prior medical records to determine eligibility including imaging, biochemical, medical, and surgical history data\n* Be willing and able to complete all aspects of the study\n* Be willing to adhere to the study visit schedule and comply with the assessments (in the opinion of the investigator).\n\nExclusion Criteria:\n\n* Subjects will be excluded, if they are children younger than age 13 years\n* Subjects that have other diseases likely to impact bone and mineral metabolism (e.g. renal, hepatic, gastrointestinal disorders, and malignancy),\n* Subjects that are currently pregnant,\n* Subjects that received medical therapy or developed any condition, which in the opinion of the investigator, could present a concern for either subject safety or difficulty with data interpretation.\n* Subjects will be excluded from Aim 2, if they are unable to tolerate supplemental phosphate.","ALL","13 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis\u002Fnephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).",[25,26,27,28,29],"Hypophosphatemia","Rickets","Hypercalciuria","XLH","HHRH","RECRUITING","2026-05-21",{"date":33,"type":34},"2026-05-27","ACTUAL",{"date":36,"type":34},"2019-01-01",{"date":38,"type":19},"2028-04",{"name":40,"class":41},"Yale University","OTHER"]